STARTUP LEGAL15 Sept 2026
PE majors eye Orbicular Pharma stake, valuation seen up to $1.5 bn | Company Business News
Orbicular Pharmaceutical Technologies, a Hyderabad-based specialty pharma firm, is exploring a stake sale. Warburg Pincus and CVC Capital Partners have shown early interest, with the deal likely valuing it at $1-1.5 billion. Jefferies is advising, and Tata Capital Healthcare Fund may exit. For investors and partners, this signals a possible ownership change ahead. Watch for official announcements before acting.
Key Statutory Highlights
- Warburg Pincus and CVC Capital Partners have shown early interest in a stake sale at Orbicular Pharmaceutical Technologies.
- The deal will likely value the Hyderabad-based company at between $1 billion and $1.5 billion.
- Jefferies is advising on the deal, and existing investor Tata Capital Healthcare Fund may partly or fully exit.
Actionable Advice for Taxpayers / Founders:If you hold shares in Orbicular or deal with the company, wait for the deal to be officially launched next quarter and terms to be public before taking any decision. Speak to your CA about the tax and structuring impact once the terms are known.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: